About Us

Bacterial and fungal respiratory infections are the main causes of morbidity and mortality in patients with cystic fibrosis.  Inhaled antibiotics play a pivotal role in CF management as the drugs are delivered directly to the site of action. Despite these advancements

CF subjects are often colonized by bacteria “resistant” to antibiotics, thereby rendering antimicrobials useless and ineffective. Furthermore increasing recognition of fungal isolates as pulmonary pathogens in patients with CF has emerged. Lung infections caused by fungal or mixed bacterial-fungal infections are known to be poor responders to antibiotic therapy. Thus, there is a critical need for the development of new antimicrobials that have a broad-spectrum of antimicrobial activity and that can be effectively used to treat resistant bacteria and fungi in CF patients.

TGV Therapeutics’ lead product is Mul-1867-CF (novel drug candidate), the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.